Study drug SX-682 with pembrolizumab for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your lung cancer is confirmed as NSCLC, and you do not have certain gene changes (EGFR, ALK, ROS1, or RET).
- Your tumor PD-L1 level is at least 1% on an approved test.
- Your cancer is metastatic (spread) or recurrent, or stage IIIC/IV that can’t be cured with surgery or radiation.
- You can provide tumor tissue from before treatment (archived sample) or agree to a biopsy, and you may need another biopsy while on treatment if it’s safe.
- Your physical function is fairly good (ECOG 0–1), and your blood counts and organ tests are high enough (platelets, neutrophils, hemoglobin, liver enzymes, kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (SX-682 plus atezolizumab) for people with advanced non-small cell lung cancer that has grown after standard treatments like immunotherapy and chemotherapy. It aims to see if the combination can help shrink or slow the cancer.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new combination of drugs (HLX07, serplulimab, and chemotherapy) for people with advanced squamous non-small cell lung cancer that hasn't been treated before. The goal is to see if this combo works better than the current standard treatments.
This trial compares pembrolizumab (an immunotherapy drug) given alone versus combined with chemotherapy for women with advanced non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if adding chemotherapy improves outcomes.
This study tests a new combination of drugs (SYHX2011, carboplatin, and an immunotherapy called enlonstobart) as the first treatment for advanced squamous lung cancer that is PD-L1 positive. The goal is to see if this combination helps shrink tumors and slow cancer growth.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy can help people with advanced non-small cell lung cancer that carries an EGFR exon 21 mutation and shows PD-L1 expression. The goal is to see if this combination helps shrink tumors or slow cancer growth more effectively.
Hear when a new Metastatic Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.